Dataset Information

Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.

ABSTRACT:

Background

The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced.

Methods

The EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers COVID-19 data from hematological malignancy patients since the pandemic's start worldwide. It spans various global locations, allowing comprehensive analysis over the first three years (2020-2022).

Findings

The EPICOVIDEHA registry collected data from January 2020 to December 2022, involving 8767 COVID-19 cases in hematological malignancy patients from 152 centers across 41 countries, with 42% being female. Over this period, there was a significant reduction in critical infections and an overall decrease in mortality from 29% to 4%. However, hospitalization, particularly in the ICU, remained associated with higher mortality rates. Factors contributing to increased mortality included age, multiple comorbidities, active malignancy at COVID-19 onset, pulmonary symptoms, and hospitalization. On the positive side, vaccination with one to two doses or three or more doses, as well as encountering COVID-19 in 2022, were associated with improved survival.

Interpretation

Patients with hematological malignancies still face elevated risks, despite reductions in critical infections and overall mortality rates over time. Hospitalization, especially in ICUs, remains a significant concern. The study underscores the importance of vaccination and the timing of COVID-19 exposure in 2022 for enhanced survival in this patient group. Ongoing monitoring and targeted interventions are essential to support this vulnerable population, emphasizing the critical role of timely diagnosis and prompt treatment in preventing severe COVID-19 cases.

Funding

Not applicable.

SUBMITTER: Salmanton-Garcia J

PROVIDER: S-EPMC10963230 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.

Salmanton-García Jon J Marchesi Francesco F Farina Francesca F Weinbergerová Barbora B Itri Federico F Dávila-Valls Julio J Martín-Pérez Sonia S Glenthøj Andreas A Hersby Ditte Stampe DS Gomes da Silva Maria M Nunes Rodrigues Raquel R López-García Alberto A Córdoba Raúl R Bilgin Yavuz M YM Falces-Romero Iker I El-Ashwah Shaimaa S Emarah Ziad Z Besson Caroline C Kohn Milena M Van Doesum Jaap J Ammatuna Emanuele E Marchetti Monia M Labrador Jorge J Zambrotta Giovanni Paolo Maria GPM Verga Luisa L Jaksic Ozren O Nucci Marcio M Piukovics Klára K Cabirta-Touzón Alba A Jiménez Moraima M Arellano Elena E Espigado Ildefonso I Blennow Ola O Nordlander Anna A Meers Stef S van Praet Jens J Aiello Tommaso Francesco TF Garcia-Vidal Carolina C Fracchiolla Nicola N Sciumè Mariarita M Seval Guldane Cengiz GC Žák Pavel P Buquicchio Caterina C Tascini Carlo C Gräfe Stefanie K SK Schönlein Martin M Adžić-Vukičević Tatjana T Bonuomo Valentina V Cattaneo Chiara C Nizamuddin Summiya S Čerňan Martin M Plantefeve Gaëtan G Prin Romane R Szotkovski Tomas T Collins Graham P GP Dargenio Michelina M Petzer Verena V Wolf Dominik D Čolović Natasha N Prezioso Lucia L Valković Toni T Passamonti Francesco F Méndez Gustavo-Adolfo GA Sili Uluhan U Vena Antonio A Bavastro Martina M Limongelli Alessandro A Duarte Rafael F RF Ledoux Marie-Pierre MP Cvetanoski Milche M Stojanoski Zlate Z Machado Marina M Batinić Josip J Magliano Gabriele G Biernat Monika M MM Pantić Nikola N Poulsen Christian Bjørn CB Cuccaro Annarosa A Del Principe Maria Ilaria MI Kulasekararaj Austin A Ormazabal-Vélez Irati I Busca Alessandro A Demirkan Fatih F Ijaz Marriyam M Klimko Nikolai N Stoma Igor I Khostelidi Sofya S Fernández Noemí N Omrani Ali S AS Bergantim Rui R De Jonge Nick N Fouquet Guillemette G Navrátil Milan M Abu-Zeinah Ghaith G Samarkos Michail M Maertens Johan J De Ramón Cristina C Guidetti Anna A Magyari Ferenc F González-López Tomás José TJ Lahmer Tobias T Finizio Olimpia O Ali Natasha N Pinczés László Imre LI Lavilla-Rubira Esperanza E Romano Alessandra A Merelli Maria M Delia Mario M Calbacho Maria M Meletiadis Joseph J Antić Darko D Hernández-Rivas José-Ángel JÁ Marques de Almeida Joyce J Al-Khabori Murtadha M Hoenigl Martin M Tisi Maria Chiara MC Khanna Nina N Barać Aleksandra A Eisa Noha N Di Blasi Roberta R Liévin Raphaël R Miranda-Castillo Carolina C Bahr Nathan C NC Lamure Sylvain S Papa Mario Virgilio MV Yahya Ayel A Aujayeb Avinash A Novák Jan J Erben Nurettin N Fernández-Galán María M Ribera-Santa Susana José-María JM Rinaldi Ikhwan I Fazzi Rita R Piedimonte Monica M Duléry Rémy R Gonzaga Yung Y Soto-Silva Andrés A Sapienza Giuseppe G Serris Alexandra A Drgoňa Ľuboš Ľ Groh Ana A Serrano Laura L Gavriilaki Eleni E Tragiannidis Athanasios A Prattes Juergen J Coppola Nicola N Otašević Vladimir V Mladenović Miloš M Mitrović Mirjana M Mišković Bojana B Jindra Pavel P Zompi Sofia S Sacchi Maria Vittoria MV Krekeler Carolin C Infante Maria Stefania MS García-Bordallo Daniel D Çolak Gökçe Melis GM Mayer Jiří J Nygaard Marietta M Hanáková Michaela M Ráčil Zdeněk Z Bonanni Matteo M Koehler Philipp P Rahimli Laman L Cornely Oliver A OA Pagano Livio L

EClinicalMedicine 20240318

<h4>Background</h4>The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced.<h4>Methods</h4>The EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers COVID-19 data ...[more]

PMID: 38533127

Similar Datasets

Project description:BackgroundNirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients.MethodsThis is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan-Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir.FindingsA total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448-4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619-8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093-0.732) and obesity (aOR 0.105, 95%CI 0.014-0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was observed explaining the mortality difference in patients after nirmatrelvir/ritonavir administration.InterpretationHaematological malignancy patients were more likely to receive nirmatrelvir/ritonavir when reporting extrapulmonary symptoms or 2nd vaccine booster at COVID-19 onset, as opposed to chronic pulmonary disease and obesity. The mortality rate in patients treated with nirmatrelvir/ritonavir was lower than in patients with targeted drugs other than nirmatrelvir/ritonavir.FundingEPICOVIDEHA has received funds from Optics COMMIT (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).

Project description:ObjectiveMost blood cancers are incurable and typically follow unpredictable remitting-relapsing pathways associated with varying need for treatment, which may be distressing for patients. Our objective was to conduct a qualitative study to explore understanding among patients with such malignancies, including the explanations given by HCPs and the impact of uncertain trajectories, to generate evidence that could guide improvements in clinical practice.MethodsThe study is set within a population-based patient cohort (the Haematological Malignancy Research Network), in which care is delivered across 14 hospitals according to national guidelines. In-depth interviews were conducted with 35 patients with chronic lymphocytic leukaemia, follicular lymphoma, marginal zone lymphoma or myeloma; and 10 accompanying relatives. Purposive sampling ensured selection of information-rich participants and the data were interrogated using reflective thematic analysis.ResultsRich data were collected and four themes (11 sub-themes) were identified: 1) Knowledge and understanding of chronic haematological malignancies; 2) Incurable but treatable; 3) Uncertainty about the future; and 4) Treatable (but still incurable): Impact on patients. Patients had rarely heard of blood cancer and many expressed difficulty understanding how an incurable malignancy that could not be removed, was treatable, often for long periods. While some were reassured that their cancer did not pose an immediate survival threat, others were particularly traumatised by the uncertain future it entailed, suffering ongoing emotional distress as a result, which could be more burdensome than any physical symptoms. Nonetheless, most interviewees understood that uncertain pathways were caused by the unpredictability of their disease trajectory, and not information being withheld.ConclusionsMany participants lacked knowledge about chronic haematological malignancies. HCPs acted to reassure patients about their diagnosis, and while this was appropriate and effective for some, it was less so for others, as the cancer-impact involved struggling to cope with ongoing uncertainty, distress and a shortened life-span.

Dataset Information

Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.

Background

Methods

Findings

Interpretation

Funding

Publications

Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets